Drug
AZD 6244 clinical trials
Also written Selumetinib, AZD6244 and ARRY-142886.
Includes 9 studies of Selumetinib sulfate.
Keep track of what changes. Save the AZD 6244 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
118 studies that test it; most in 2014 (14); 1 more planned to start later
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 4 |
| 2007 | 7 |
| 2008 | 1 |
| 2009 | 10 |
| 2010 | 13 |
| 2011 | 7 |
| 2012 | 9 |
| 2013 | 8 |
| 2014 | 14 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 8 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 4 |
| 2021 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 11
Who runs them
Industry 39 · Other 80
National Cancer Institute (NCI) (37) · AstraZeneca (35) · M.D. Anderson Cancer Center (4) · Merck Sharp & Dohme LLC (3) · UNICANCER (2) · University of Birmingham (2) · The Christie NHS Foundation Trust (2) · Beijing Tiantan Hospital (2)
Often tested with
Tested in the same studies.
Olaparib (8) · MK 2206 (7) · Durvalumab (6) · Vistusertib (6) · Capivasertib (5) · Docetaxel (5) · AZD4547 (4) · Erlotinib (4)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses AZD 6244 is read from its arms, and is right about nine times in ten.
Testing it · 119
- Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT07619521Written as Selumetinib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Selumetinib Sulfate
- Study of Cabozantinib With Selumetinib for Plexiform NeurofibromasRecruitingPhase 1Girish Dhall, MDNCT06502171Written as Selumetinib Oral Capsule
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade GliomaRecruitingPhase 3National Cancer Institute (NCI)NCT04166409Written as Selumetinib Sulfate
- Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNSTRecruitingPhase 1/2AeRang KimNCT06735820Written as Selumetinib
- Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)Not yet recruitingPhase 2Beijing Tiantan HospitalNCT07713745Written as Selumetinib 25mg/m2
- Selumetinib for NF2-Related SchwannomatosisNot yet recruitingPhase 2Beijing Tiantan HospitalNCT07707947Written as Selumetinib
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Selumetinib
- Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1RecruitingPhase 2University of Alabama at BirminghamNCT06188741Written as Selumetinib
- Selumetinib and Azacitidine in High Risk Chronic Blood CancersRecruitingPhase 1University of ChicagoNCT03326310Written as Selumetinib
- Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese ChildrenNot yet recruitingPhase 2West China HospitalNCT06763315Written as Selumetinib
- The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate CapsuleNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06621082Written as Selumetinib
- Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate CapsuleNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06620354Written as Selumetinib
- Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03581487Written as Selumetinib
- Selumetinib and Olaparib in Solid TumorsActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT03162627Written as Selumetinib
- AZD6244 Hydrogen Sulfate for Children With Nervous System TumorsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01362803Written as AZD6244
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingPhase 1AstraZenecaNCT02546661Written as Selumetinib
- Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade GliomaActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01089101Written as Selumetinib
- MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02407405Written as Selumetinib
- Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid MalignanciesActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01364051Written as Selumetinib
See all 119 studies that test AZD 6244 →
Given in every arm · 7 — AZD 6244 is usual care beside what is tested
- Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05554328Written as Selumetinib Sulfate
- A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade GliomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT04576117Written as Selumetinib Sulfate
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingPhase 2AstraZenecaNCT03944772Written as Selumetinib
- Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLCCompletedPhase 1Canadian Cancer Trials GroupNCT01783197Written as Selumetinib
- A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursCompletedPhase 1AstraZenecaNCT02586987Written as Selumetinib
- MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)WithdrawnPhase 2M.D. Anderson Cancer CenterNCT03004105Written as Selumetinib
- Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By SurgeryCompletedPhase 2National Cancer Institute (NCI)NCT01206140Written as Selumetinib
Codes
What other systems call AZD 6244 · ClinicalTrials.gg INT005047
- RxNorm 2289380One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 2289380 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.